NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a collaboration with Mayo Clinic to support a newly funded research program evaluating a novel treatment approach for pediatric diffuse midline glioma (DMG), one of the most aggressive childhood brain cancers. The program is supported by a grant from the Children’s Cancer Research Fund (CCRF) awarded to Mayo Clinic investigators Dr. David Daniels and Dr. Liang Zhang.
The research aims to address a fundamental challenge in treating malignant brain tumors: achieving and maintaining therapeutic drug concentrations within the tumor. While convection-enhanced delivery (CED) allows drugs to bypass the blood-brain barrier through direct intracranial infusion, therapeutic benefit may be limited by rapid drug clearance from the treatment site. The Mayo Clinic team will evaluate a combination therapy strategy designed to enhance intratumoral drug retention by modulating drug efflux mechanisms, with the goal of prolonging therapeutic exposure following localized delivery. The project will begin with large animal studies, and if successful, may expand to human studies in the future.
The study will utilize NeuroOne’s investigational drug delivery neural device technology, which combines precision intracranial drug delivery with simultaneous neural recording. This integrated approach enables targeted therapy while providing real-time physiologic monitoring throughout treatment, offering investigators additional insight into drug delivery and its effects on the surrounding neural environment. The CCRF award represents a milestone in advancing this therapeutic approach toward clinical evaluation.
This collaboration expands NeuroOne’s growing portfolio of drug delivery initiatives, reflecting increasing interest from academic investigators and biopharmaceutical companies in the platform. David Wambeke, Chief Business Officer of NeuroOne, said, “This collaboration with Mayo Clinic represents another important milestone in the continued expansion of our drug delivery platform. We believe our technology has the potential to become an enabling platform for targeted intracranial therapies by combining precision drug delivery with real-time neural recording.”
NeuroOne markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. The Company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. More information is available at nmtc1.com.
